Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 658 of 5804
-
New hope for rare blood cancer: drug combo targets hard-to-treat lymphoma
Disease control Recruiting nowIt is an open-label, multicenter, phase II, single arm trial to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients about 28 patients with Relapsed or Refractory Plasmablastic lymphoma.
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug shows promise against tough cancers in first chinese trial
Disease control OngoingResearchers are looking for a better way to treat advanced Triple-Negative Breast Cancer (TNBC) and Non-Small-Cell Lung Cancer (NSCLC). "Advanced" usually means that the cancer keeps growing even with treatment. The cancer may also be "metastatic", which means that it has spread …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Blood pressure trial aims to keep Seniors' minds sharp
Prevention Recruiting nowThe PCOT study is a multi-site randomized trial of patients 70 years or older with high BP. The main goal of the study Preventing Cognitive Decline by Reducing BP Target Trial (PCOT) is to conduct a large pragmatic clinical trial (PCT) to test the hypothesis that patients who rec…
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Jun 27, 2026 08:01 UTC
-
One pill could change the fight against sleeping sickness in kids
Disease control CompletedAcoziborole has been studied in an open-label pivotal Phase II/III trial (DNDi-OXA-02-HAT) in the DRC and Guinea. As the numbers of reported cases diminish, resources for surveillance and specialised screening will also taper. This decrease, coupled with the loss of diagnostic sk…
Phase: PHASE2, PHASE3 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Blood test may guide chemo choices for colon cancer patients
Disease control Recruiting nowThis Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo aims to supercharge prostate cancer radiation
Disease control Recruiting nowThis phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abemaciclib is in a class of medi…
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a Twice-Yearly shot stop artery plaque from growing?
Disease control OngoingCKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's vessels as measured by coronary computed tomography an…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New antibody cocktail shields vulnerable patients from COVID-19
Prevention CompletedA weak immune response to two doses of vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been observed in immunocompromised patients, including solid organ transplant recipients (SOTRs)1,2,3. Studies focused on third dose in SOTRs revealed that the …
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo aims to shrink rectal tumors before surgery
Disease control TerminatedThis clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as …
Phase: PHASE1 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Bladder cancer drug combo shows promise in patients who Can't have chemo
Disease control CompletedThe purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill shows promise for sickle cell sufferers
Disease control CompletedThis study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination of two medicines (decitabine-tetrahydrouridine). Both medicines are new for the treatment of sickle cell disease. Participants who a…
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug aims to heal hearts after attack – trial results awaited
Disease control CompletedThis is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction (MI). This study consists of a screening period (t…
Phase: PHASE2 • Sponsor: Cardior Pharmaceuticals GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Aggressive cholesterol drugs may shrink artery plaque in young patients
Disease control Recruiting nowThis study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Engineered immune cells take aim at childhood cancers
Disease control Recruiting now3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This …
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could a fraction of the usual radiation be enough? new trial aims to reduce treatment burden for lymphoma patients.
Disease control Recruiting nowThe MIR study proved the effect of Rituximab in combination with a localized irradiation given in a standard dose. Together with the TROG 99.03 trial, this led to the recommendation of using this combined approach in early stage nodal follicular lymphoma. The GAZAI study is curre…
Phase: PHASE3 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug shows promise for SMA patients in major trial
Disease control OngoingThis trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of nusinersen and/or risdiplam and/or have a history of onasemnogene abeparvovec, compared to placebo.
Phase: PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingPembrolizumab monotherapy and platinum-based chemotherapy in the combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have been widely used in daily clinical practice based on the KEYNOTE-048 study. On the other hand, doceta…
Phase: PHASE2 • Sponsor: Hokkaido University Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:28 UTC
-
HIV patients may ditch daily pills for Twice-Yearly antibody shots
Disease control CompletedTMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test various doses of the combination of the antibodies for safety and pharmacokinetics …
Phase: PHASE1, PHASE2 • Sponsor: TaiMed Biologics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug may help kids with rare liver disease avoid transplant
Disease control ENROLLING_BY_INVITATIONAn Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Quick HIV test at birth could get infants on better meds faster
Disease control OngoingThis study is being conducted to explore the feasibility of implementing targeted birth HIV testing of high-risk neonates using facility-based point-of-care (POC) HIV diagnostics, and to improve the ability to implement the best standard-of-care treatment possible. Infants found …
Phase: PHASE4 • Sponsor: Harvard School of Public Health (HSPH) • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC